IngredientsCasein (pronounced /ˈkeɪsiːn/; from the Latin caseus, meaning "cheese") is a family of related phosphoproteins — designated αS1, αS2, β, and κ — that are commonly found in mammalian milk, comprising about 80% of the proteins in cow's milk and between 20% and 60% of the proteins in human milk. Casein is a mixture of phosphoproteins of differing molecular weight. It is a high molecular weight phosphoprotein with good nutritional value and functional properties.
The isoelectric point of casein is 4.6. In pure form, it is an amorphous white solid, tasteless and odourless, while its commercial type is yellowish with a pleasing odour. Unlike many proteins, casein is not coagulated by heat.
Casein proteins are unique to milk and provide infant mammals with essential amino acids, and also bind calcium and phosphorus required for skeletal growth. Human breast milk is approximately 40% casein and 60% whey, while cow's milk is 80% casein and 20% whey. Cow's milk contains about 3% casein by weight. Sheep and cow milk have a higher casein content than other types of milk, with human milk having a particularly low casein content.
Bovine milk casein is mainly composed of four unique proteins: αs1, αs2, β, and κ-casein. A repulsive charged protein layer on the surface of the casein micelles, comprised of the hydrophilic part of κ-casein (commonly referred to as caseinomacropeptide [CMP] or glycomacropeptide [GMP]), ensures their colloidal stability at the native pH of milk. The casein proteins, apart from being distinguished by their amino acid sequences and their tendency to form dimers, trimers, and higher oligomers, carry different amounts of phosphate and carbohydrate groups.
Separation of caseins from whey proteins is traditionally carried out by selective precipitation of the casein fraction, while keeping the whey proteins in solution. The two most common practices are separation by isoelectric precipitation or by selective hydrolysis with the enzyme chymosin (commonly known as rennet). Once precipitated, the product is either dried as is, or resolubilized using a caustic solution and dried to obtain caseinate.
The principal commercial forms of casein include:
Casein can be ingested as a protein supplement in powder form or through milk, cheese, yogurt, butter, and other dairy products. Casein can also be used as a functional ingredient in the food industry, such as an emulsifier and thickener.
The production of cheese — and by extension the exploitation of casein — predates recorded history, beginning well over 7,000 years ago. Cheesemaking may have originated from nomadic herdsmen who stored milk in vessels made from sheep's and goats' stomachs. Cheesemaking is documented in Egyptian tomb drawings and in ancient Greek literature. Because stomach linings contain a mix of lactic acid, bacteria, and rennet, the milk would ferment and coagulate, yielding a product from which — through gentle agitation and separation of curds from whey — cheese was produced; cheese being essentially a concentration of the major milk protein, casein, and milk fat.
Neolithic pottery sieves were used to separate curds from whey during cheesemaking 5,000 to 5,500 BC in the same way that is still practiced today. Preserved cheese dating from 1615 BC was found in the Taklamakan Desert in Xinjiang, China. Until its modern spread along with European culture, cheese was most common in Europe and the Middle East and North Africa.
The Latin word caseus (cheese) gave us the English word "casein," while the term formaticum — meaning cheese shaped in a mold — evolved into the French fromage, Italian formaggio, and several other European words for cheese. Homer describes Polyphemus curdling half his milk and setting it aside in wicker strainers — a process remarkably similar to how traditional fresh cheeses are still made today, and is often considered the oldest recorded description of practical cheesemaking.
After the fall of the Roman Empire, the development of cheesemaking in Europe slowed, and cheese became a localized product associated more with peasant life than noble tables. However, during the Middle Ages, monks in European monasteries became key innovators in cheese production. Casein-based ingredients have a long history of use, in both food and non-food applications, due to the ease with which their functional properties can be manipulated.
Mass-produced rennet became available in the 1860s, eliminating the need for each cheesemaker to source enzymes from animal stomachs. Cheese is a type of dairy product produced by coagulation of the milk protein casein; during production, milk is usually acidified and either the enzymes of rennet or bacterial enzymes with similar activity are added to cause the casein to coagulate, after which the solid curds are separated from the liquid whey and pressed into finished cheese.
The hydrolyzed form of casein is frequently used by clinical researchers, but is not very popular as a general dietary supplement because casein is favored for its slow digestion and absorption. As a targeted dietary supplement specifically for muscle recovery and athletic performance, casein protein powders rose to widespread use during the late twentieth century, following research on protein digestion kinetics in the 1990s.
Casein has been traditionally defined as composed of three fractions — α, β, and γ — according to electrophoretic mobility (Hipp et al., 1952). Today casein is defined according to the amino acid sequences of each of the subgroups αS1, αS2, β, and κ. β-casein alone exists in at least 13 different protein variants, each contributing to milk's protein and calcium content.
Casein protein is a complete protein, which means it contains all of the amino acids that the body is not able to make on its own. The only amino acid that casein products may be low in is cysteine. Casein contains a large amount of proline. The abundance of proline residues is mechanistically significant: the presence of Pro and Pro-Pro residues at the C-terminus of a peptide chain enables it to remain intact during gastrointestinal digestion, confirming the isolation of several anti-hypertensive peptides from casein, as they possess a high amount of Pro.
Casein micelles provide something else important for growth beyond amino acids: calcium and phosphorus. The protein composition of milk makes it a great source of calcium and phosphorus, important minerals the body needs. These minerals are physically integrated within the micellar structure and are released during digestion.
Digestion of casein releases a range of bioactive peptides encrypted within the primary protein sequence. The major classes include:
The unique structure of casein proteins — called the casein micelle — makes them harder to break apart and requires a longer digestion time compared to whey proteins. When casein reaches the acidic environment of the stomach, it forms a gel or clot, which slows gastric emptying and results in a gradual, sustained release of amino acids into the bloodstream. This property is especially beneficial for overnight muscle maintenance or for providing satiety between meals.
Whey protein is characterized as a rapidly digestible protein source, with ingestion resulting in a fast, but transient post-prandial increase in plasma amino acid concentrations. In contrast, micellar casein is a more slowly digestible protein source with ingestion resulting in a moderate, but more prolonged post-prandial increase in plasma amino acid concentrations.
Muscle protein synthesis was increased for 3.5 hours after whey protein ingestion, whereas muscle protein synthesis was increased for up to 6 hours after casein protein ingestion.
Bioactive peptides derived from dietary proteins, notably casein (the αs1-casein fragment 90–94), exhibit ligand activity for the calcium-sensing receptor (CaSR), a G-protein-coupled receptor found on enteroendocrine L-cells. Binding of peptides to CaSR initiates downstream signaling through the Gαq/11 subunit, which activates phospholipase C (PLC), facilitating the breakdown of phosphatidylinositol 4,5-bisphosphate into inositol trisphosphate (IP₃), which subsequently releases calcium ions from endoplasmic reticulum reserves, and the increased cytosolic Ca²⁺ concentration initiates vesicular exocytosis, enhancing the production of glucagon-like peptide-1 (GLP-1).
This is the most extensively researched application of casein as a dietary supplement, with a substantial body of human clinical evidence.
Whey protein is typically considered more potent at stimulating muscle protein synthesis rates when compared to micellar casein. This has been, at least partly, attributed to the more rapid protein digestion and amino acid absorption rates following ingestion of whey compared to micellar casein protein. The research consensus characterizes casein as a "slow" protein that produces a sustained but lower-peak anabolic response compared to "fast" whey protein.
The concept of pre-sleep protein ingestion has been introduced as a way to increase overnight muscle protein synthesis rates when exercise is performed prior to bed-time. Previous research has shown that overnight muscle protein synthesis rates tend to be lower than those typically observed in the morning following an overnight fast.
In the study by Res et al., recreational athletes performed a single bout of resistance-type exercise in the evening; to maximize the immediate muscle protein synthetic response following exercise, all participants ingested 60 g of carbohydrates and 20 g of whey protein immediately after exercise. In addition, subjects were provided with either 40 g of casein protein or a placebo drink (water) immediately prior to sleep. Muscle protein synthesis rates were approximately 22% higher during overnight sleep when protein was consumed prior to sleep compared to participants ingesting the placebo drink.
The current data shows that the ingestion of 20–40 g of casein approximately 30 min before sleep stimulates whole-body protein synthesis rates over a subsequent overnight period (preceded or not by resistance exercise) in young and elderly individuals. In addition, pre-sleep protein consumption can augment the muscle adaptive response (muscle fiber cross-sectional area, strength, and muscle mass) during 10–12 weeks of resistance exercise in young, but not in elderly men.
A study involving healthy young men showed that 40 g of casein protein ingested 30 minutes before sleep following resistance training was digested and absorbed well during sleep. Circulating amino acid levels increased rapidly, resulting in increased whole-body protein synthesis rates and improved protein balance, inducing positive effects on muscle recovery.
Snijders et al. (2015) in the Journal of Nutrition found that 12 weeks of pre-sleep casein supplementation (27.5 g protein) combined with resistance training resulted in greater strength and muscle mass gains compared to a placebo group, with no increase in body fat.
However, some studies in the literature have reported that pre-sleep casein ingestion has no significant or only limited effects on recovery and performance outcomes. The discrepancies between findings may be attributed to various physiological and methodological factors, including differences in the timing of casein administration, the dosage used, the scheduling and intensity of exercise protocols, the extent of exercise-induced muscle damage, and the lack of dietary controls.
Evidence strength: Moderate-to-strong for the acute effect of 40 g casein before sleep on overnight muscle protein synthesis; moderate for chronic muscle mass and strength gains. Evidence in older adults is more limited. Some studies show no significant effect, and the field notes significant methodological heterogeneity across trials.
Emerging evidence in soccer players indicates that pre-sleep casein (40 g) accelerates functional recovery, improving countermovement jump performance and reactive strength index 24 hours post-match compared with placebo. Pre-sleep ingestion of casein may be particularly beneficial for athletes engaged in sports that require explosive strength, while post-exercise consumption may be more appropriate for those aiming to enhance anaerobic power output and reduce fatigue index.
Evidence supports that a high proportion of calories from protein increases weight loss and prevents weight regain. Proteins are known to induce satiety, increase secretion of gastrointestinal hormones, and increase diet-induced thermogenesis, but less is known about whether various types of proteins exert different metabolic effects.
In the Western world, dairy protein, which consists of 80% casein and 20% whey, is a large contributor to daily protein intake. Casein and whey differ in absorption and digestion rates, with casein being a "slow" protein and whey being a "fast" protein. Data indicate that whey is more satiating in the short term, whereas casein is more satiating in the long term.
One randomized, parallel-design 12-week-long study enrolled seventy subjects with a BMI between 25 and 40 kg/m² aged 18–65 years, randomized into a glucose control group, a casein group, or a whey group. A Visual Analogue Scale (VAS) was used to measure subjective sensations of appetite. Results showed significantly higher satiety in the whey group compared with the casein or control groups when measured before lunch at both 6 and 12 weeks (P=0.017 and P=0.025, respectively). This trial found whey to be superior to casein at acute pre-meal satiety, though both dairy proteins outperformed the carbohydrate control in some measures.
Evidence strength: Moderate for a general satiety-promoting effect of high-protein diets; weaker and mixed for casein specifically compared to other protein sources. The distinction in satiety kinetics (short-term vs. long-term) is supported by clinical data but the practical significance for weight loss outcomes is not firmly established.
CPP-ACP-based products have been evaluated for clinical efficacy in the remineralization of white spot lesions (WSLs). Research has indicated that CPP-ACP is anticariogenic and capable of reversing the early stages of enamel lesions in vitro and in clinical research.
A systematic review registered in the PROSPERO database (CRD42024540595), which analyzed fourteen clinical articles meeting inclusion criteria, found that CPP-ACP is clinically effective in promoting the remineralization of WSLs, although the results were inconsistent across studies. Comparisons with placebo and resin infiltration treatments revealed greater efficacy for CPP-ACP. The combination of CPP-ACP with fluoride appeared to further enhance the remineralizing effect on WSLs. Additional standardized clinical studies with longer follow-up periods are warranted to confirm these outcomes.
Numerous studies have found that casein phosphopeptides are capable of protecting teeth against erosion by enhancing enamel remineralization and reducing demineralization.
Evidence strength: Moderate, based on systematic reviews of randomized controlled clinical trials. Results are inconsistent across studies. The combination of CPP-ACP with fluoride shows the most consistent clinical benefit. Evidence is primarily from dental/clinical research rather than general nutritional supplementation.
Research has focused on the state-of-the-art of peptides with inhibitory activity towards angiotensin I-converting enzyme (ACE) — thus with anti-hypertensive potential — derived from enzymatic hydrolysis of caseins. The key peptides studied include isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), derived from β-casein and κ-casein.
The tripeptide Val-Pro-Pro was detected in the abdominal aorta of spontaneously hypertensive rats (SHR), indicating that this tripeptide is resistant against serum peptidases, while ACE inhibitory peptide purified from α-casein was not able to lower blood pressure due to susceptibility to digestive enzymes. This finding illustrates the critical importance of peptide stability for bioavailability.
The antihypertensive product Calpis sour milk (Calpis Food Industry Co., Ltd., Tokyo, Japan) contains the tripeptides IPP and VPP, derived from casein. A meta-analysis (Turpeinen et al., 2013, Ann Med) examined antihypertensive effects of these bioactive tripeptides. Overall, the clinical translation of ACE-inhibitory casein peptides to meaningful blood pressure reductions in humans remains modest, and most studies demonstrating ACE inhibition use in vivo or in vitro systems.
Evidence strength: Preliminary to moderate. The mechanism (ACE inhibition) is established in vitro. Some human studies and fermented milk products show small but statistically significant reductions in blood pressure, but the magnitude of clinical effect is modest and evidence is not consistent across all trials.
Milk proteins are known for their high nutritional quality, based on their essential amino acid composition, and they exhibit a wide range of bioactivities, including satiety, antimicrobial, mineral-binding, and anti-lipidemic properties. Over the past 30 years, peptides encrypted in the primary amino acid sequences of proteins and released along with amino acids during digestion are increasingly recognized as biologically active protein metabolites that may have beneficial effects on human health. Because of its low pH qualities, casein is often characterized as a slow-digesting protein, which tends to enhance satiety and prolong the post-prandial period.
Protein anabolism after exercise was reported to be better maintained after the ingestion of casein protein compared to whey protein. This finding refers specifically to a longer-duration net positive protein balance due to casein's reduced protein breakdown, even if peak rates of synthesis are lower compared to whey.
Recent evidence underscores the superiority of bioactive peptides over intact proteins in influencing satiety, glucose homeostasis, and lipid metabolism. Peptide fractions from plant and animal sources have demonstrated antihypertensive and insulin-sensitizing effects in clinical trials, independent of total protein intake. Clinical studies targeting a clear understanding of the gastrointestinal stability, bioavailability, and safety of food-based peptides are still warranted.
Evidence strength: Preliminary. Most mechanistic data are from in vitro and animal studies. Clinical evidence in humans for casein-specific glycemic or lipidemic effects independent of general high-protein diet effects is limited and inconsistent.
Casein is available in the following supplement forms:
Casein is the primary allergenic protein in cow's milk, contributing to the worldwide escalating prevalence of food allergies. Casein protein is a natural part of cow's milk, and many people with an allergy to cow's milk are allergic to casein protein. Casein content accounts for about 80% of milk protein content, of which α-casein (including αs1 and αs2-CN) accounts for about 80% of casein content. As a non-existent part of human milk, α-casein is most likely to cause allergies.
By analyzing linear B-cell epitope, T-cell epitope, and allergenic peptides, the strongest casein allergenicity is observed for cow milk, followed by goat milk, while the casein of mare milk has the weakest allergenicity. Among casein subtypes, α-CN is the most allergenic protein, followed by κ-CN.
Complications of milk protein allergies may include nutritional and growth impairment, anemia, and insufficient bone calcification. Symptoms of non-IgE-mediated allergy to food proteins are mostly gastrointestinal and include malabsorption, bloody diarrhea, emesis, pallor, lethargy, and weight loss.
Casein protein comes from cow's milk, which also contains lactose. Some casein protein products, including micellar casein, may contain lactose in small or large amounts. Individuals with lactose intolerance should check product labels and may prefer highly purified casein isolates with minimal residual lactose.
Common side effects of casein protein supplementation include diarrhea, gas, or an upset stomach, although different forms of casein may cause different side effects.
Casein protein may be available as hydrolyzed casein (casein hydrolysate) or micellar casein, and these two forms of casein protein may have different effects and side effects. Hydrolyzed casein was absorbed more rapidly than intact casein and the absorption rate of hydrolyzed casein approached the rate of whey.
The FDA has not reviewed casein protein for safety and effectiveness as a dietary supplement. Casein and its derivatives are, however, classified as GRAS (Generally Recognized as Safe) for use as food ingredients when used in accordance with good manufacturing practices in the United States.
Certain casein proteins, specifically αS1- and β-casein, have been reported to be very stable to heat treatment, remaining detectable even after baking in a food matrix. This heat stability has implications for individuals with casein allergy, as standard cooking may not fully denature or destroy the allergenic proteins.
No specific, well-documented pharmacokinetic drug interactions with casein as a dietary supplement were identified in peer-reviewed sources. As a high-calcium protein source, casein supplementation could theoretically influence the absorption of certain minerals (e.g., iron, zinc) when consumed simultaneously, consistent with general knowledge of protein-mineral interactions, though specific clinical interaction data for casein supplements specifically were not found in the identified peer-reviewed literature.
Health conditions that Casein may help support.
Bioactive peptides derived from casein hydrolysates exhibit antioxidant properties, scavenging free radicals and reducing oxidative stress markers in vitro and in some animal models. Casein hydrolysates produced by high hydrostatic pressure plus proteolytic enzymes show antioxidant and anti-inflammatory activities in cell studies. Human evidence is limited, with most data from in vitro and preclinical systems.
As a high-quality, slowly digested protein, casein contributes to satiety and appetite suppression, though some evidence suggests whey may produce greater acute satiety signaling. Multiple controlled trials and a PMC review found that casein and whey protein produce broadly similar reductions in appetite at matched doses, particularly above a protein threshold of ~25% of energy intake. Casein is recognized as contributing to greater fullness versus carbohydrates.
Casein supplementation supports strength and lean mass gains over long-term resistance training. When total protein intake is matched, casein produces hypertrophy and strength outcomes comparable to whey protein. Presleep casein also accelerates functional recovery in competitive athletes, enabling more consistent performance across training blocks.
Hydrolyzed casein yields bioactive peptides that inhibit angiotensin-converting enzyme (ACE), reducing blood pressure. A 2025 double-blind randomized placebo-controlled trial in 114 prehypertensive/hypertensive adults found that hydrolyzed casein peptides (HCP-C7C12) significantly reduced systolic blood pressure by 9.41% and diastolic blood pressure by 9.53% over 8 weeks. A meta-analysis confirmed that casein-derived lactotripeptides reduce both systolic and diastolic blood pressure across randomized clinical trials.
Casein plays a unique role in calcium transport and absorption via casein phosphopeptides (CPPs), which prevent the formation of insoluble calcium salts and enhance calcium bioavailability in the small intestine. Epidemiological and clinical data link higher dairy protein (including casein) intake to greater bone mineral density. Enzyme-specific casein hydrolysates have been shown to enhance calcium absorption and osteoblast activation.
Casein has been studied against soy protein for effects on plasma lipoprotein profiles. Compared to soy protein, casein is associated with lower lipoprotein(a) concentrations but higher LDL cholesterol, suggesting casein may not be optimal for LDL-lowering versus plant proteins. Meta-analyses of milk protein more broadly show modest improvements in cholesterol with supplementation in metabolic disease populations.
Casein is used as part of protein-based nutritional interventions targeting sarcopenia—the age-related loss of muscle mass and strength. A 2025 systematic review and meta-analysis identified casein alongside whey and plant proteins as key components of multinutritional supplementation strategies for sarcopenia in older adults. Maintaining adequate protein synthesis via casein may help counteract muscle loss associated with aging.
Casein supplementation has been studied for body composition improvement, including fat loss and lean mass preservation during caloric restriction. Its high satiety value and sustained protein release support caloric control and muscle retention. Clinical research supports casein's use in weight management formulations, particularly when combined with exercise.
Casein's slow-release amino acid profile makes it particularly effective for overnight muscle recovery. A systematic review found that ~20–40 g of casein consumed ~30 minutes before sleep improves overnight protein synthetic response in healthy young men following evening resistance exercise. A clinical trial in professional soccer players found presleep casein significantly attenuated muscle soreness and accelerated functional recovery at 12 and 36 hours post-match compared to placebo.
Clinical evidence shows presleep casein supplementation can reduce exercise-induced muscle soreness. In a RCT with professional soccer players, muscle soreness measured by visual analogue scale was significantly lower with casein at 12 hours post-match compared to control. The sustained amino acid delivery of casein is thought to support repair processes during overnight recovery.
Casein, specifically as casein phosphopeptide (CPP) complexed with amorphous calcium phosphate (ACP), is a well-studied biomimetic remineralizing agent. CPP-ACP stabilizes supersaturated calcium and phosphate in plaque, delivering these ions to demineralized enamel. A meta-analysis found clinically significant short-term remineralization effects in in situ trials.
Casein supplementation has been associated with reductions in postprandial triglyceride levels. One study in overweight individuals found casein reduced postprandial triglycerides by 22%. A meta-analysis of 65 RCTs covering milk proteins found improvements in triglycerides with high-quality protein supplementation in adults with metabolic diseases.
Body systems that Casein may help support.
Go back